Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life.

ABSTRACT:

Aims

Hyperkalaemia (HK) is common in heart failure (HF) patients, related to renal dysfunction and medical treatment. It limits medical therapy optimization, which impacts prognosis. New potassium (K) binders help control HK, allowing better medical management of HF.

Methods and results

A retrospective multicentre register included all outpatients with HF and HK (K ≥ 5.1 mEq/L) treated with patiromer according to current recommendations. We evaluated analytic and clinical parameters before starting the treatment and at 7, 30 and 90 days, as well as adverse events related to patiromer and treatment optimization. We included 74 patients (71.6% male) with a mean age of 70.8 years (SD 9.2). Sixty-seven patients (90.5%) presented HK in the previous year. Forty patients (54.1%) un

SUBMITTER: Esteban-Fernandez A 

PROVIDER: S-EPMC9715760 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature